Clinical Trial Detail

NCT ID NCT02685826
Title A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene Corporation
Indications

multiple myeloma

Therapies

Dexamethasone

Durvalumab + Lenalidomide

Age Groups: adult

No variant requirements are available.